Akebia Therapeutics (AKBA) Net Income towards Common Stockholders Growth (1y) (2014 - 2026)
Akebia Therapeutics (AKBA) Net Income towards Common Stockholders Growth (1y) (2014 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 44.51 Bn | 43.55 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.52 Bn | 39.86 Bn | 2.15 Bn | -304.98% |
| 3 | Zoetis | 32.43 Bn | 30.75 Bn | 1.05 Bn | -5.04% |
| 4 | Takeda Pharmaceutical | 28.63 Bn | 22.83 Bn | 5.10 Bn | -17.29% |
| 5 | United Therapeutics | 21.87 Bn | 19.21 Bn | 683.80 Mn | 7.59% |
| 6 | Viatris | 18.98 Bn | 18.09 Bn | 1.46 Bn | -2,482.61% |
| 7 | Neurocrine Biosciences | 15.43 Bn | 15.04 Bn | 935.80 Mn | 34.33% |
| 8 | Elanco Animal Health | 12.02 Bn | 11.49 Bn | 798.00 Mn | 390.91% |
| 9 | Dr Reddys Laboratories | 10.14 Bn | 9.98 Bn | - | - |
| 10 | Akebia Therapeutics | 244.72 Mn | 89.17 Mn | 38.70 Mn | -3,706.48% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -3,706.48% |
| Mar 31, 2026 | -248.13% |
| Dec 31, 2025 | 46.31% |
| Sep 30, 2025 | 102.69% |
| Jun 30, 2025 | 102.88% |
| Mar 31, 2025 | 133.98% |
| Dec 31, 2024 | -3,814.01% |
| Sep 30, 2024 | -38.30% |
| Jun 30, 2024 | 23.18% |
| Mar 31, 2024 | 33.08% |
| Dec 31, 2023 | 114.89% |
| Sep 30, 2023 | 73.22% |
| Jun 30, 2023 | -137.94% |
| Mar 31, 2023 | 57.68% |
| Dec 31, 2022 | 93.95% |
| Sep 30, 2022 | 9.15% |
| Jun 30, 2022 | 135.46% |
| Mar 31, 2022 | 6.10% |
| Dec 31, 2021 | 22.91% |
| Sep 30, 2021 | 0.69% |